The bluebird bio Inc. is a clinical stage biotechnology firm. It is focused on transforming patient lives with sever genetic and orphan diseases. Today, it announced the closing of its initial public offering. The IPO offered 6,832,352 shares that were priced at US$17 per share piece. Underwriters were given the option to acquire 891,176 additional shares of common stock. All shares for the initial public offering were offered by bluebird bio. The firm's common stocks were listed under the trading symbol "BLUE" in the NASDAQ Global Select Market.

Bank of America Merrill Lynch and JP Morgan Securities LLC acted as joint book running managers for the offering. Cowen and Company acted as lead manager while Canaccord Genuity Inc. and Wedbush PacGrow Life Sciences are acting as co-managers.

Based in Cambridge, bluebird bio Inc. has a world class team driven towards the transformation of its patients and their families and a broad platform on gene therapy.